The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the ...
Despite so many genetic discoveries, ease for a genetic test and even exome sequencing, it is almost impossible to conduct a diagnostic approach for hereditary neurological diseases without semiotic ...
Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease is the most common dominantly-inherited ataxia. Although there is no cure, our group and others have been shown that RNA interference ...
dDepartment of Neurology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil eDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results